倍他乐克在慢性心力衰竭中的应用

Betaloc applied in the chronic heart failure

目的观察比较倍他乐克在治疗慢性心衰病人中的疗效。方法146例慢性心衰患者随机分成两组,一组给予倍他乐克6.25 mg,口服,每天2次;另一组为空白对照,给予安慰剂,口服,每天2次,疗程均为1个月。结果两组采用不同药物治疗的患者群体短期死亡率方面χ2=0.098,P>0.05,两样本率间差异没有统计学意义;在1年内并发症出现率χ2=3.982,P<0.05,长期预后方面χ2=4.419,P<0.05,差异有统计学意义。结论小剂量倍他乐克选择性阻断β1受体,降低心肌的耗氧量,对抗儿茶酚胺的心脏毒性作用,在改善症状、防止并发症、改善患者长期预后等方面,倍他乐克要优于对照组。

Objective Aim to investigate the effect of betaloc applied in the chronic heart failure. Methods One hundred and six patients of chronic heart failure were divided into two groups by random. The group of betaloc apply 6.25 mg betaloc, po, bid. The group herbesser apply 90 mg herbesser, po. qd. Course of treatment was a month. Results There was no distinguish between the two groups about the deatl3 rate of short term, x^2 = 0. 098 , P 〉 0.05. There are distinguish between the two groups about the complications, x^2 = 3. 982, P 〈 0.05 and the long - term, x^2 = 4. 419, P 〈 0.05. Conclusion Minidose betaloc can block the β1 receptor selectivity, degrade consumed oxygen of myocardium and ant- catecholamine, then it can prevent the complications and improve the long - term. So betaloc is better than contral group in chronic heart failure.